Azenta (NASDAQ:AZTA - Free Report) had its target price boosted by Needham & Company LLC from $55.00 to $59.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.
Separately, Stephens reissued an "overweight" rating and issued a $60.00 target price on shares of Azenta in a research note on Thursday, January 2nd.
Read Our Latest Stock Report on AZTA
Azenta Stock Performance
NASDAQ AZTA traded down $4.81 on Thursday, hitting $47.51. 1,126,374 shares of the stock traded hands, compared to its average volume of 471,804. Azenta has a 12 month low of $38.82 and a 12 month high of $67.77. The business's fifty day moving average is $50.61 and its two-hundred day moving average is $48.94. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -15.94 and a beta of 1.47.
Azenta (NASDAQ:AZTA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.03. Azenta had a positive return on equity of 1.25% and a negative net margin of 24.91%. Analysts expect that Azenta will post 0.42 EPS for the current fiscal year.
Insider Transactions at Azenta
In other news, CFO Herman Cueto sold 712 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $40.07, for a total value of $28,529.84. Following the completion of the sale, the chief financial officer now directly owns 23,892 shares in the company, valued at $957,352.44. This represents a 2.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director William L. Cornog acquired 12,500 shares of the firm's stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $39.60 per share, for a total transaction of $495,000.00. Following the purchase, the director now directly owns 14,755 shares of the company's stock, valued at approximately $584,298. This trade represents a 554.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 1,423 shares of company stock worth $57,020 over the last three months. 10.62% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Azenta
Institutional investors have recently bought and sold shares of the stock. State Street Corp grew its holdings in Azenta by 0.4% during the 3rd quarter. State Street Corp now owns 1,686,993 shares of the company's stock valued at $81,718,000 after buying an additional 6,398 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Azenta by 65.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,577,881 shares of the company's stock valued at $78,894,000 after purchasing an additional 621,830 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Azenta by 1.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,317,385 shares of the company's stock worth $65,922,000 after purchasing an additional 18,529 shares during the last quarter. Royce & Associates LP raised its stake in Azenta by 2.4% during the fourth quarter. Royce & Associates LP now owns 758,068 shares of the company's stock valued at $37,903,000 after purchasing an additional 18,091 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Azenta by 11.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 461,603 shares of the company's stock worth $23,080,000 after buying an additional 48,064 shares in the last quarter. 99.08% of the stock is owned by hedge funds and other institutional investors.
About Azenta
(
Get Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Featured Articles
Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
